Italy Cancer Pain Management Market Analysis Report [2022-30]

Italy Cancer Pain Management Market Analysis

$ 3999

Italy's Cancer Pain Management market is projected to grow from $156.48 Mn in 2022 to $227.69 Mn by 2030, registering a CAGR of 4.8% during the forecast period of 2022-2030. The main factors driving the growth would be technological developments in pain management methods and government initiatives. The market is segmented by drug type and by disease. Some of the major players include Molteni Farmaceutici (ITA), Italfarmaco (ITA), Grunenthal Pharma, Pfizer, and Abbott.

ID: IN10ITHS002 CATEGORY: Healthcare Services GEOGRAPHY: Italy AUTHOR: Neha Davda

Buy Now

Italy Cancer Pain Management Market Executive Summary

Italy's Cancer Pain Management market is projected to grow from $156.48 Mn in 2022 to $227.69 Mn by 2030, registering a CAGR of 4.8% during the forecast period of 2022 - 2030. In 2019, Italy spent $2,906 per person on healthcare or 8.67% of its GDP. In 2019, health spending lagged substantially behind the EU average in both per capita spending and as a percentage of GDP. Approximately 74% of health spending in 2019 was supported by the government, which is less than the 80% average for the EU.

Several illnesses of acute and chronic pain are related to cancer. Gene alterations brought on by cancer affect essential cell-regulatory proteins. These changes encourage abnormal cell behaviour, which then fuels unchecked cell proliferation and the ensuing destruction of neighbouring healthy tissues. By pressing on bones, nerves, and other body parts, these tumours put pressure on the body and cause pain. Cancer pain can also be felt while undergoing severe cancer therapy, particularly in more advanced stages of the disease. In addition to having some of the top pharmaceutical companies actively involved in the development of novel analgesics, Europe is a recognised player in the global market for the treatment of cancer pain.

italy cancer pain management market analysis

Market Dynamics

Market Growth Drivers

The market for cancer pain management in Italy is anticipated to expand as a result of technological developments in pain management methods and goods, such as the creation of new, more potent painkillers and the rise in the use of minimally invasive procedures. Moreover, The Italian government has worked to increase cancer patients' access to pain-management therapies. For instance, the National Cancer Plan has provisions to better manage pain associated with cancer, such as boosting access to specialised pain clinics and the availability of painkillers.

Market Restraints

Despite growing recognition of the need for adequate pain management for cancer patients, Italian patients still lack understanding and education, which may restrict access to efficient pain management treatments. Further, strict regulatory regulations tend to postpone the approval and introduction of novel pain management medicines and limit the accessibility of some goods to patients apply to the Italian market for cancer pain management treatments and limit the market growth.

Competitive Landscape

Key Players

Molteni Farmaceutici (ITA)
Italfarmaco (ITA)
Grunenthal Pharma
Pfizer
Abbott

Healthcare Policies and Regulatory Landscape

The European Medicines Agency (EMA) and the Italian Ministry of Health oversee the regulatory framework for the market for cancer pain management in Italy. The National Health Service (NHS) in Italy is in charge of administering medical care and paying for prescription drugs. Prior to being marketed in Italy, all pain management medications, including those used to treat cancer pain, must have clearance from the Italian Medicines Agency (AIFA). The approval procedure entails a detailed assessment of the drug's efficacy and safety as well as proof of its affordability.

Reimbursement Scenario

The National Health Service (NHS) controls the majority of the reimbursement conditions for the Italian cancer pain management market. In Italy, the NHS is in charge of covering all necessary medications, including those used to treat cancer pain. Drug producers and the NHS negotiate prices to determine reimbursement for cancer pain medications, with the final price dependent on the drug's therapeutic value. Drugs with a high perceived therapeutic benefit and a favourable cost-effectiveness ratio are more likely to be reimbursed with favourable terms.

1. Executive Summary
1.1 Service Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Healthcare Services Market in Country
1.6 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Market Size (With Excel and Methodology)
2.2 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Services
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Cancer Pain Management Market Segmentation

By Drug Type (Revenue, USD Billion):

Non-steroidal anti-inflammatory medicines relieve pain at the site of injury by blocking the cyclooxygenase enzyme, which prevents prostaglandin formation. NSAIDs are a class of medications that includes medications with analgesic, antipyretic, and, at higher doses, anti-inflammatory properties.

Opioids
Morphine
- Fentanyl
- Others
Non-Opioids
Acetaminophen
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
Nerve Blockers

By Disease Indication (Revenue, USD Billion):

Based on disease Indication the market is segmented into:

Lung Cancer
Colorectal cancer
Breast cancer
Prostate cancer
Blood cancer
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.